Q-linea
@q-linea.bsky.social
Innovating infectious disease diagnostics to help clinicians act faster. ASTar® delivers rapid AST results in ~6 hours to support better therapy decisions and reduce broad‑spectrum antibiotic use. Website: https://qlinea.com
MIC-informed beta-lactam dosing is moving from concept to bedside practice. A new international consensus guidance highlights the role of beta-lactam dose individualization and MIC-informed PK/PD targets in critically ill patients. Full paper: accpjournals.onlinelibrary.wiley.com/doi/10.1002/...
𝗪𝗲'𝗿𝗲 𝗮𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴 𝗔𝗗𝗟𝗠 𝟮𝟬𝟮𝟲 𝘁𝗵𝗶𝘀 𝘄𝗲𝗲𝗸 𝗶𝗻 𝗔𝗻𝗮𝗵𝗲𝗶𝗺. Looking forward to connecting with the laboratory medicine community and joining discussions on the future of infectious disease diagnostics. 𝗚𝗲𝘁 𝗶𝗻 𝘁𝗼𝘂𝗰𝗵 𝘁𝗼 𝗺𝗲𝗲𝘁 𝘄𝗶𝘁𝗵 𝗼𝘂𝗿 𝘁𝗲𝗮𝗺: sales.us@qlinea.com: US sales@qlinea.com: EMEA #IDsky #ADLM2026
Q-linea will be at the Alabama Infectious Diseases Society (ALIDS) meeting 2026! Meet the team to learn more about the important role ASTar plays in clinical care and antimicrobial stewardship. #RapidAST #ClinicalMicrobiology
For resistant bloodstream infections, every antibiotic dose matters. Walker et al. found DTR Gram-negative infections were associated with 40% higher mortality, while 77% of patients received discordant empiric therapy. pubmed.ncbi.nlm.nih.gov/41903557/ #IDSky
A recent IDSE article highlighting diagnostic innovations presented at IMARI 2026 featured all three posters presented by our team. The research explored the clinical and operational impact of rapid phenotypic AST in bloodstream infections. 🔗 www.idse.net/Diagnostics-... #IDSE #RapidAST
New ASTar® vs standard of care publication (Microbiology Spectrum, US). High agreement (≥94% CA; ≥97% EA); ~42h earlier targeted therapy. Could impact therapy in ~51% of cases, many enabling de-escalation. 🔗 journals.asm.org/doi/10.1128/... #RapidAST #ClinicalMicrobiology
We’re pleased to be attending the Unite for Sepsis Symposium, hosted by Sepsis Alliance, starting today. Bringing together experts across the care pathway to explore advances in sepsis prevention, diagnosis, treatment, and recovery. #SepsisAwareness #ClinicalMicrobiology #IDsky
#ASMMicrobe2026 in Washington, D.C. has come to a close. Thank you to everyone who visited our booth and joined the discussions. We appreciated the strong interest in ASTar® and conversations around rapid AST. Our customer poster is now available on our website: qlinea.com/us/resources/ #IDsky
Don’t miss our customer poster at ASM Microbe 2026. We’re supporting a customer presentation featuring ASTar®, on the impact of rapid phenotypic AST on antibiotic de‑escalation. Poster 187 (HEALTH‑SUN‑187) 📅 June 7 | 12:30–2:00pm | Poster Hall WEWCC #ASMMicrobe2026 #IDsky
Great to see strong engagement at #ASMMicrobe2026. Thank you to everyone who has visited Booth #1609 and joined discussions on rapid AST and its role in clinical decision‑making. Looking forward to continuing the conversations and the upcoming poster session this weekend. #IDsky
ASM Microbe 2026 has started in Washington, D.C. Visit Q-linea at Booth #1609 to learn about ASTar® and rapid AST. We’re also supporting a customer poster on rapid phenotypic AST and antibiotic de‑escalation. Poster 187 (HEALTH‑SUN‑187) 📅June 7 | 12:30–2:00 pm | Poster Hall WEWCC #ASMMicrobe2026
𝗧𝗼𝗱𝗮𝘆 𝗶𝘀 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝘂𝘀 𝗗𝗶𝘀𝗲𝗮𝘀𝗲𝘀 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗶𝘀𝘁𝘀 𝗗𝗮𝘆. ID pharmacists play a key role in antimicrobial stewardship, guiding evidence‑based therapy, supporting care teams, and helping optimize treatment decisions to improve patient outcomes and address antimicrobial resistance. #IDPharmacistsDay #AMR
MAD‑ID 2026 in Orlando has come to an end. Thanks to everyone who visited our booth, joined the poster session, and engaged in discussions. We appreciated the interest in ASTar® and how it can support timely treatment decisions and improve outcomes for patients. #IDSky
We’re at the MAD‑ID 2026 Annual Meeting in Orlando, bringing together the infectious diseases and clinical microbiology community for scientific exchange and discussion. Find the Q-linea team at Booth #308 at the Hyatt Regency Orlando. We’ll present two posters on May 15, 5:00–6:30 pm. #MADID2026
We’re attending the NYCASM Spring Meeting today in New York City, bringing together clinical microbiology and infectious disease experts for a day of discussion and case‑based insights. We look forward to connecting with the microbiology community throughout the day. #NYCASM2026 #IDSky
We’re taking part in A New Chapter in Vigor Microbiology, an educational workshop in Belgrade bringing together laboratory professionals for scientific exchange and discussion. Join us tomorrow, May 8, from 10am–1pm. #clinicalmicrobiology
New ASTar® publication in Microbiology Spectrum reports the first US study evaluating ASTar performance and turnaround time. Key findings: • ASTar results 38.1 h faster vs standard of care • Earlier results could have influenced therapy in 83% of cases 🔗 journals.asm.org/doi/10.1128/... #IDSky
Be sure to check out Dr. Vikas Gupta as he shares his work at #ESCMIDGlobal2026! He highlights findings which demonstrate that remnant suspension from ASTar enabled high performance pathogen ID & genotypic testing with future potential to reduce costs related to automated multiplex platforms 🔬
SCACM Spring Meeting workshop | April 14, 2–3 pm ET Emilia Marrero-Greene (Lakeland Regional Health) presents a laboratory evaluation of rapid AST and ASTar® and potential impact on lab processes and patient outcomes. Real‑world laboratory experience 🔗 scacm27.wildapricot.org/2026_Spring_... #SCACM
South Central Association for Clinical Microbiology - 2026 Spring SCACM
scacm27.wildapricot.org
We’re Q-linea, delivering rapid phenotypic AST to infectious disease care. With ASTar®, susceptibility results from positive blood cultures are available in ~6 hours, giving clinical teams the clarity to act earlier and more precisely. #AMR #ClinicalMicrobiology #IDSky
